来源：环球市场播报 诺瓦瓦克斯公司（纳斯达克股票代码：NVAX）周四股价上涨，此前该公司公布了2025年第四季度及全 年财务业绩。 每股收益 诺瓦瓦克斯报告第四季度每股收益为11美分，与去年同期每股亏损51美分相比实现扭亏。第四季度营收 为1.47亿美元，同比增长67%。 "随着2026年有一个强劲的开局，包括最近宣布的与辉瑞的Matrix-M协议，我们期待合作伙伴在商业和 临床开发方面的执行，推动我们的研发工作，并在我们利用技术推动疫苗创新和价值创造的过程中，期 待更多潜在的合作机会，"雅各布斯周四评论道。 业绩指引 诺瓦瓦克斯强调了2026年的营收预测，预计调整后总营收在2.3亿至2.7亿美元之间，而市场普遍预期为 3.8122亿美元。 公司预计实现Nuvaxovid产品销售额3500万至4500万美元，以及调整后供应销售额4000万至5000万美 元，这反映了与血清研究所等合作伙伴的持续合作。 技术分析 目前，该股交易价格较其20日简单移动平均线（SMA）高出8.4%，较其100日SMA高出9.2%，显示出短 期强势。在过去12个月中，股价大幅上涨，目前更接近其52周高点而非低点，反映出强劲的上升趋势。 ...

Core Viewpoint - The article discusses recent developments in the pharmaceutical industry, particularly focusing on new drug applications and innovations in cancer treatment, highlighting the competitive landscape and market potential for various companies involved in drug development [5][12][20]. Group 1: New Drug Applications - From May 24 to May 30, the National Medical Products Administration received applications for 9 new chemical drugs and biological products from 6 listed companies [5]. - Companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and Kangfang Biotech each submitted 2 clinical applications, while others like Canaan and Bai Jie Shen Zhou submitted 1 application each [6]. Group 2: Key Innovations in Cancer Treatment - Kangning Jereh's KN035, a subcutaneous PD-L1 inhibitor, has been submitted for clinical trials, potentially becoming the first of its kind globally. It targets multiple indications, with 3 applications already submitted and 7 ongoing clinical studies [12][13]. - KN035 offers advantages over traditional intravenous methods, including better patient compliance and reduced costs, which could enhance its market share [13]. - The competitive landscape includes existing PD-L1 inhibitors like Merck's Atezolizumab and AstraZeneca's Durvalumab, with KN035 targeting different cancer types [14]. Group 3: Dual Antibody Developments - Kangfang Biotech's AK104, a PD-1/CTLA-4 dual-specific antibody, has received approval for clinical trials, with 13 indications currently in phase II trials [17]. - The dual antibody approach is gaining traction due to the limitations of existing PD-1/L1 therapies, which have low efficacy rates in solid tumors [18]. - The market for dual antibodies is expected to grow significantly, with 217 candidates in various clinical stages globally [19]. Group 4: COVID-19 Vaccine Developments - CanSino's inhaled COVID-19 vaccine is in phase II trials and is applying for emergency use, which could enhance public acceptance due to its non-invasive administration method [20][21]. - Sinovac has expanded the emergency use of its vaccine to children aged 3 and above, with positive safety and efficacy results from clinical trials [24][25].

Core Viewpoint - Xizang Pharmaceutical has a strong profitability driven primarily by its flagship product, "Xinhuosuo," but faces challenges in diversifying its product portfolio and addressing market expectations for future growth [1][3][4]. Financial Performance - The company has recorded profits exceeding 1 billion, ranking fifth in the biopharmaceutical sector, with a total market capitalization of 15 billion and a valuation of 15 times earnings, placing it at the lower end of profitable companies [1]. - Recent financial records show profits of 2.09 billion, 3.70 billion, 8.01 billion, and 10.51 billion over the last four years, indicating a consistent upward trend [1]. - Xinhuosuo accounted for approximately 88% of the company's revenue in the first half of 2025, generating 14.56 billion out of a total of 16.51 billion [1][6]. Product Overview - The product lineup is heavily reliant on Xinhuosuo, with other products contributing only 11.64% to total revenue [3][7]. - Xinhuosuo, launched in 2005, is the first gene-engineered drug for acute heart failure treatment in China, with plans to expand production capacity to 15 million units annually starting in 2025 [4][6]. - The drug's clinical advantages include rapid onset of action within 30 minutes, compared to traditional medications that take 1-2 hours, and it protects kidney function while promoting sodium excretion [4][6]. Strategic Challenges - The company has faced two significant strategic failures: the acquisition of the drug "Yimuduo" and a failed investment in a COVID-19 mRNA vaccine [9][12]. - The acquisition of Yimuduo for 1.9 billion USD has resulted in substantial impairment losses totaling approximately 766 million RMB due to underperformance and market challenges [11]. - The investment in the Russian mRNA vaccine project has also led to financial losses and strategic setbacks, with the project ultimately being terminated [13][12]. Shareholder Dynamics - The company's ownership structure is complex, with the largest shareholder, Lin Gang, controlling 38.11% of the shares, while the founder, Chen Dabin, retains a significant but minority stake [20][23]. - There is ongoing tension between the controlling shareholder and the founding group, leading to strategic disagreements and governance challenges [24]. Future Outlook - The market exclusivity for Xinhuosuo is expected to last until 2033, but future revenue will depend on the successful expansion into new indications and the transition to water-based injections [7][6]. - The company is exploring collaborations with SGLT2 inhibitors to enhance treatment outcomes for chronic heart failure [6].

Group 1 - The FDA continues to approve updated COVID-19 vaccine boosters for elderly and immunocompromised populations [1]